Core Insights - The company reported a revenue of 741,287,436.95 yuan for the third quarter of 2025, representing a year-on-year growth of 3.48% [1] - The net profit attributable to shareholders of the listed company was 1,681,675.27 yuan, showing a significant year-on-year increase of 106.13% [1]

Core Viewpoint - The company reported a slight increase in revenue and net profit for the first three quarters of 2025, indicating stable growth despite a challenging market environment [1] Financial Performance - The company's operating revenue for the first three quarters reached 2.201 billion yuan, representing a year-on-year growth of 2.99% [1] - The net profit attributable to shareholders was 16.3491 million yuan, showing a year-on-year increase of 3.21% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 24.6698 million yuan, reflecting a significant year-on-year growth of 34.71% [1] - Basic earnings per share stood at 0.11 yuan [1]

Core Viewpoint - The company reported a slight increase in revenue and net profit for the first three quarters of 2025, indicating stable growth despite a challenging market environment [1] Financial Performance - The company's operating revenue for the first three quarters reached 2.201 billion yuan, representing a year-on-year growth of 2.99% [1] - The net profit attributable to shareholders was 16.3491 million yuan, showing a year-on-year increase of 3.21% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 24.6698 million yuan, reflecting a significant year-on-year growth of 34.71% [1] - Basic earnings per share were reported at 0.11 yuan [1]

第三届董事会第三十四次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 一、董事会会议召开情况 证券代码：301239 证券简称：普瑞眼科 公告编号：2025-048 普瑞眼科医院集团股份有限公司 本议案已经第三届董事会审计委员会审议通过。 表决情况：同意7票，反对0票，弃权0票。 三、备查文件 普瑞眼科医院集团股份有限公司（以下简称"公司"）第三届董事会第三 十四次会议通知于2025年10月21日以书面、电子邮件的方式向全体董事发出并 送达，会议于2025年10月24日以现场结合通讯方式召开。本次会议应出席董事7 人，实际出席董事7人。会议由董事长徐旭阳先生主持，公司全体高级管理人员 列席会议。本次会议的召集、召开和表决程序符合《中华人民共和国公司法》 （以下简称"《公司法》"）等法律、法规、规范性文件以及《公司章程》的 有关规定。 二、董事会会议审议情况 经与会董事认真审议，表决了以下议案： （一）审议通过《关于公司<2025年第三季度报告>的议案》 经审议，董事会认为：公司《2025年第三季度报告》的编制和审议程序符 合法律、行政法规、中国证 ...

Financial Performance - Total revenue for Q3 2025 reached ¥741,287,436.95, an increase of 3.48% year-over-year[5] - Net profit attributable to shareholders was ¥1,681,675.27, representing a significant increase of 106.13% compared to the same period last year[5] - The net profit after deducting non-recurring gains and losses was ¥3,888,911.87, up 114.40% year-over-year[5] - Basic earnings per share for Q3 2025 was ¥0.01, reflecting a growth of 105.56% compared to the previous year[5] - Total operating revenue for the period reached ¥2,200,549,440.39, an increase from ¥2,136,699,863.80 in the previous period, representing a growth of approximately 3.9%[18] - Net profit for the period was ¥21,588,547.06, slightly down from ¥22,845,948.88, reflecting a decrease of approximately 5.5%[19] - The total comprehensive income for the period was CNY 21,588,547.06, compared to CNY 22,845,948.88 in the previous period[20] - Basic and diluted earnings per share remained stable at CNY 0.11 for both periods[20] Assets and Liabilities - Total assets as of September 30, 2025, amounted to ¥4,606,956,437.82, a slight increase of 0.19% from the end of the previous year[5] - Total liabilities decreased to ¥2,465,547,256.68 from ¥2,476,861,122.42, a reduction of approximately 0.5%[17] - Total assets increased to ¥4,606,956,437.82 from ¥4,598,026,724.34, indicating a growth of about 0.2%[17] - Long-term equity investments increased to ¥207,109,185.61 from ¥170,089,374.50, reflecting a growth of about 21.8%[16] Cash Flow - Cash flow from operating activities for the year-to-date was ¥414,125,450.17, showing a slight decrease of 0.08% compared to the previous year[5] - The net cash flow from operating activities was CNY 414,125,450.17, slightly down from CNY 414,469,212.80 in the previous period[22] - Cash inflow from operating activities totaled CNY 2,236,276,463.31, an increase from CNY 2,184,953,764.81 year-over-year[22] - Net cash flow from investing activities decreased by 51.03% to -300,349,269.24 RMB, as all hospitals under construction have opened, leading to a significant reduction in fixed investments[10] - The net cash flow from investing activities was -CNY 300,349,269.24, improving from -CNY 613,278,600.03 in the previous period[23] - Cash and cash equivalents at the end of the period were CNY 376,140,370.20, down from CNY 479,822,198.29 at the end of the previous period[23] - The total cash outflow from financing activities was CNY 298,538,469.65, compared to CNY 606,582,850.80 in the previous period[23] Shareholder Information - The total number of common shareholders at the end of the reporting period was 10,438, with no preferred shareholders having restored voting rights[10] - Chengdu Puri Century Investment Co., Ltd. holds 35.91% of shares, amounting to 53,729,585 shares, with 24,941,200 shares pledged[10] - Xu Xuyang, a natural person, holds 6.75% of shares, totaling 10,100,000 shares, with 7,575,000 shares under lock-up[10] - The top ten shareholders collectively hold significant stakes, with the largest shareholder holding nearly 36% of the total shares[11] - The total number of unrestricted shares held by the top ten unrestricted shareholders is 78,829,585 shares[13] - The company has a high concentration of ownership, with the top shareholder being the actual controller of several management partnerships[11] - There are no preferred shareholders or changes in restricted shares reported for the current period[12] Operational Costs and Expenses - Total operating costs amounted to ¥2,105,665,391.88, up from ¥2,058,379,113.42, indicating an increase of about 2.3%[18] - Research and development expenses increased by 65.77% to ¥8,086,821.35, primarily due to higher IT R&D costs[9] - The company experienced a 295.01% decline in investment income, resulting in a loss of ¥2,523,117.09, mainly due to increased losses from joint ventures[9] - The company's cash and cash equivalents decreased to ¥376,140,370.20 from ¥481,067,596.27, a decline of about 21.8%[15] - Accounts receivable increased to ¥104,567,385.64 from ¥101,080,594.08, showing a growth of approximately 4.9%[15] - Inventory rose to ¥186,303,726.69 from ¥148,312,611.64, marking an increase of about 25.6%[16] - Total current assets slightly increased to ¥873,122,319.94 from ¥869,259,065.91, a growth of approximately 0.3%[16]

证券代码：301239 证券简称：普瑞眼科 公告编号：2025-047 普瑞眼科医院集团股份有限公司 | 是否 | 为控 | | | | | | | | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 是 | 股股 | 否 | 质 | | | | | | | | | | | | | | | | 股 | 东或 | 质 | 为 | 本次质押 | 占其所 | 占公司 | 是否 | 质押 | 押 | 东 | 第一 | 质权 | 押 | | | | | | 补 | 数量 | 持股份 | 总股本 | 为限 | 起始 | 到 | 名 | 大股 | 人 | 用 | （股） | 比例 | 比例 | 售股 | 充 | 日 | 期 | | 称 | 东及 | 途 | 质 | 日 | 其一 | | | | | | | | | | | | | | 押 | 致行 | | | | | | | | | | | | | | | | | ...

一、募集资金的基本情况 经中国证券监督管理委员会《关于同意成都普瑞眼科医院股份有限公司首 次公开发行股票注册的批复》（证监许可[2022]587号）同意注册，普瑞眼科医 院集团股份有限公司（以下简称"公司"）首次公开发行人民币普通股（A股） 股票37,404,762股，每股面值人民币1.00元，每股发行价格为33.65元，募集资 金总额为1,258,670,241.30元，扣除发行费用（含税）后，实际募集资金净额 为1,098,935,692.69元。 天健会计师事务所（特殊普通合伙）已于2022年6月27日对公司上述募集资 金到位情况进行了审验，并出具了天健验[2022]314号《成都普瑞眼科医院股份 有限公司验资报告》。 二、本次募集资金专户的开立情况和监管协议的签署情况 证券代码：301239 证券简称：普瑞眼科 公告编号：2025-046 普瑞眼科医院集团股份有限公司 关于签订募集资金专户存储四方监管协议的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 3、丙方作为甲方的保荐机构，应当依据有关规定指定保荐代表人或者其他 工作人员对甲方募集资金使用 ...

Market Overview - The medical services sector experienced a decline of 0.9% on October 22, with Sanbo Brain Science leading the drop [1] - The Shanghai Composite Index closed at 3913.76, down 0.07%, while the Shenzhen Component Index closed at 12996.61, down 0.62% [1] Stock Performance - Notable gainers in the medical services sector included: - Yaokang Biological (688046) with a closing price of 17.18, up 2.81% [1] - Aoyang Health (002172) with a closing price of 4.26, up 1.91% [1] - Haochen Medical (002622) with a closing price of 3.32, up 1.84% [1] - Significant decliners included: - Sanbo Brain Science (301293) with a closing price of 57.19, down 4.67% [2] - Chengda Pharmaceutical (301201) with a closing price of 33.98, down 4.50% [2] - XD Haoyuan Medical (688131) with a closing price of 79.90, down 2.07% [2] Capital Flow - The medical services sector saw a net outflow of 615 million yuan from institutional investors, while retail investors contributed a net inflow of 370 million yuan [2][3] - Key stocks with notable capital flows included: - Kanglong Chemical (300759) with a net inflow of 46.59 million yuan from institutional investors [3] - Aoyang Health (002172) with a net inflow of 10.44 million yuan from institutional investors [3] - Yaokang Biological (688046) with a net inflow of 9 million yuan from institutional investors [3]

Group 1 - The company announced the nomination of candidates for its fourth board of directors, including three non-independent directors and two independent directors [1] - The nominated non-independent directors are Xu Xuyang, Cao Changliang, and Hou Ping [1] - The nominated independent directors are Tang Huadong and Zou Huan [1]

普瑞眼科医院集团股份有限公司 董事会议事规则 第一章 总则 第一条 为了保护公司和股东的合法权益，规范董事的行为，理顺公司管理 体制，明晰董事会的职责权限，建立规范化的董事会组织架构及运作程序，保 障公司经营决策高效、有序地进行，依照《中华人民共和国公司法》《中华人民 共和国证券法》《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市 公司自律监管指引第 2 号——创业板上市公司规范运作》等其他规范性文件以 及《普瑞眼科医院集团股份有限公司章程》（以下简称"公司章程"）的规定， 制定本规则。 第二章 董事会的组成和组织机构 第二条 公司依法设立董事会，董事会是公司的常设机构，是公司经营决策 机构，行使法律法规以及公司章程规定的职权，对股东会负责并向其报告工作。 第三条 公司董事会由五名董事组成，其中独立董事两名。公司设董事长一 人，由董事会以全体董事的过半数选举产生。公司独立董事占董事会成员的比 例不得低于三分之一，且至少包括一名会计专业人士。 公司董事协助董事长工作，董事长不能履行职务或者不履行职务的，由半 数以上董事共同推举一名董事履行职务。 第四条 公司设董事会秘书 1 名，由董事会聘任。董事会秘书 ...